Asahi Kasei Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Asahi Kasei Corporation
Korea Q1 Roundup: Mixed Earnings Amid M&A, Prescription Sales
Large Korean pharma firms’ first-quarter earnings were mostly mixed on a range of diverse factors such as solid prescription sales and impacts from acquisitions, with some even looking to space for new business opportunities.
Minute Insight: Xeltis’ Vascular Access Graft Stays Patent In First-In-Human Trial
Xeltis’ aXess graft demonstrated high patency rates and no infections after six months in the first-in-human trial.
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.
Minute Insight: Xeltis Expects The US Trial Of 'Living' Vascular Graft To Start This Year
Xeltis hemodialysis access graft, made of its proprietary electrospun supramolecular polymer material, is advancing in clinical trials in Europe and will likely be ready for a US trial by the end of this year, according to the company.
- Medical Devices
- Other Names / Subsidiaries
- Advanced Circulatory Systems, Inc.
- Artisan Pharmaceuticals
- Asahi Kasei Holdings US, Inc.
- Asahi Kasei Pharma America Corp. (AKP America)
- Cardiac Science Corporation
- Golden Hour Data Systems, Inc.
- Kyma Medical Technologies, Ltd.
- Mobilize RRS LLC.
- TherOx, Inc.
- Veloxis Pharmaceuticals Inc.
- ZOLL Medical Corporation
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.